EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective.
Saved in:
| Title: | EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective. |
|---|---|
| Authors: | Parackal, A1 (AUTHOR), Ting, E2 (AUTHOR), Verhoek, A3 (AUTHOR), Joy, A4 (AUTHOR), Sehdev, S5 (AUTHOR), Hettle, R6 (AUTHOR) |
| Source: | Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS115-S116. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2024.03.616 |
